细胞疗法治疗股骨头坏死的证据:文献系统综述
该系统综述纳入11项证据等级III级及以上的研究、共683例股骨头坏死,评估细胞疗法的临床疗效、影像学结构改善、翻修率和安全性。报告患者报告结局的10项研究均显示细胞疗法组优于对照组;细胞疗法组影像学进展24.5%(93/380髋)低于对照组40%(98/245髋),全髋关节置换转换率16%(62/380髋)低于对照组21%(52/252髋),并发症率低(<3%)且无严重不良事件。作者指出纳入研究及所用细胞疗法存在显著异质性,需明确特定临床适应证并实现细胞疗法标准化。
要点
- 报告患者报告结局的10项研究均显示细胞疗法组结局优于对照组。
- 细胞疗法组影像学进展24.5%(93/380髋)低于对照组40%(98/245髋)。
- 细胞疗法组全髋关节置换转换率16%(62/380髋)低于对照组21%(52/252髋),并发症率<3%且无严重不良事件。
核心结论
- 细胞疗法治疗股骨头坏死已被报告为安全,并提示可改善临床结局、降低疾病进展率。
- 纳入研究及所用细胞疗法存在显著异质性,需明确特定临床适应证并实现细胞疗法标准化。
研究设计与样本
- 系统综述,纳入证据等级III级及以上的研究,共筛选1483篇文章,最终纳入11项研究(6项I级、1项II级、4项III级),包括683例股骨头坏死。
主要发现
- 报告患者报告结局的10项研究均显示细胞疗法组结局优于对照组。
- 细胞疗法组影像学进展24.5%(93/380髋),对照组为40%(98/245髋)。
- 报告失败率的10项研究中有9项显示细胞疗法组全髋关节置换转换率16%(62/380髋),对照组为21%(52/252髋)。
- 并发症率低(<3%),无严重不良事件。
局限性
- 纳入研究存在显著异质性。
- 所用细胞疗法存在显著异质性。
- 研究在细胞来源、细胞表征、辅助治疗和结局评估方面差异很大。
- 需明确特定临床适应证并实现细胞疗法标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-therapy has been promoted among the therapeutic arsenal that can aid in bone formation and remodeling, in early stages of osteonecrosis of the femoral head (ONFH). The purpose of this systematic review was to assess the evidence supporting the (1) clinical efficacy; (2) structural modifying effect, as evaluated radiographically; (3) revision rates; and (4) safety of cell-therapy for the treatment of ONFH. METHODS: A systematic review was performed including studies with a level-of-evidence of III or higher. A total of 1483 articles were screened. Eleven studies met the criteria for inclusion in this review (level-of-evidence: 6 level-I, 1 level-II, and 4 level-III), including 683 cases of ONFH. RESULTS: All 10 studies that reported patient-reported outcomes showed improved outcomes in the cell-therapy groups compared with the control group. Overall, 24.5% (93/380 hips) that received cell-therapy showed radiographic progression compared with 40% (98/245 hips) in the control group. Nine of 10 studies that reported failure rates showed a lower total hip arthroplasty conversion rate in the cell-therapy group 16% (62/380 hips) compared with the control group 21% (52/252 hips). There was a low complication rate (<3%) with no major adverse effects. CONCLUSION: Cell-therapies for the treatment of ONFH have been reported to be safe and suggest improved clinical outcomes with lower disease progression rate. However, there was substantial heterogeneity in the included studies, and in the cell-based therapies used. Specific clinical indications and cell-therapy standardization are required because studies varied widely with respect to cell sourcing, cell characterization, adjuvant therapies, and assessment of outcomes.
引用
- Piuzzi NS, Chahla J, Schrock JB, et al. Evidence for the Use of Cell-Based Therapy for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature. J Arthroplasty. 2017. PMID: 28162838. doi:10.1016/j.arth.2016.12.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。